Dr Mukesh Kumar
He is the cofounder and Technical Lead at Bailrigg Diagnostics Limited. Dr Kumar has been named as a finalist at the 2017 MIT Technology Review’s ‘Innovators Under 35 Europe’ awards in recognition for his work on technology to help improve clinical blood testing. With over 10 years of extensive research experience he has managed a range of Medical Technology. Having worked with various microelectronic manufacturing companies, he has the breadth of experience to transfer the research output from laboratory to industrial applications. An 'entrepreneurial team' under his leadership called “eBIOGEN” was declared the first runner up at an International business plan competition organised in India (2011). The business plan was also shortlisted for the finals at the world’s richest business competition, ‘RBPC 2012’ in Houston. Dr Kumar’s research activities have been supported by various research grants such as Japan Society for the Promotion of Science (JSPS, London), Higher Education Innovation Fund (HEIF, UK), Engineering and Physical Sciences Research Council (EPSRC, UK) and Leverhulme Grant, etc. Dr Kumar graduated with BEng (First Class Honours) and a PhD Physics from Lancaster University. He has co-authored a number of high impact journals, and filed 2 patents, with more patents in preparation.
She is a chemist with over 8 years of work experience in various roles in academia and industry. She has been awarded some competitive research grants in the UK and she worked as a PhD researcher at Lancaster University before co-founding Bailrigg Diagnostics. Rashmi is responsible for the lab operation and project management. She has been pro-active to develop and refine the business plan for the company. She holds a BSc Chemistry First class honours and a postgraduate degree with 1st class Distinction. Incidentally she has also co-founded Bailrigg Immunodiagnostics Ltd, a start-up that focuses on the development of rapid and sensitive cardiac blood tests to address some unmet clinical needs.Rashmi is currently developing a rapid healthcare assay (point-of-care testing) that provides a measurement in minutes compared to hours, currently, for acute myocardial infarction (MI), where morbidity increases significantly with diagnosis time.
Dr Bob Lauder
He is a technical adviser (Biomedical and Life Sciences) to eBiogen. Dr Lauder is a senior lecturer in immunochemistry in Biomedical and Life Sciences at Lancaster University. His research interest is in elucidating the structure and function of glycosaminoglycans (GAGs) and the proteoglycans (PGs). Dr Lauder’s lab examines the mechanisms of bacterial toxin production. His research also includes Protein Biochemistry, Diagnosis in Biomedicine, Cell Signalling, Pathobiology.
Prof Peter Fielden
He is a technical adviser (Science and Technology) to eBiogen. Prof Fielden is the Head of Chemistry at Lancaster University. Peter’s research is focused on analytical science - the quantitative measurement of chemical and biochemical species in a diversity of environments. Electrokinetic separation systems, with a special emphasis on the technique of isotachophoresis, have been applied to a diverse range of measurement challenges. Such sensing and separation systems may be integrated with micro-fluidics and lab-on-a-chip devices. He has extensive experience of working with start-ups.
Michael Mumford, FCCA
He is a former Head of the Accounting and Finance Department and chair of the Management School Board of Studies at Lancaster University, and a company director with broad academic and business experience in the UK and abroad. He has a Lifetime Achievement Award from the British Accounting Association (BAA), and acts as business mentor to eBiogen.
Dr David Telford
He is a clinical adviser to eBiogen. Dr Telford is a microbiology and infection control consultant at University Hospitals of Morecambe Bay NHS Trust, with over 30 years of clinical work experience in National Health Service hospitals. He has strong interests in near patients testing, including near-real time monitoring of medical conditions. Dr Telford has published 45 papers, mainly in the areas of sudden infant death syndrome and the environmental ecology of Campylobacter infection. He is a professional member of the American Society of Microbiologists, British Infection Society and the British Medical Association, and a Fellow of the Royal College of Pathologists